KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $43.9 million.

  • Biogen's Capital Expenditures rose 1170.48% to $43.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $153.8 million, marking a year-over-year increase of 6.51%. This contributed to the annual value of $153.8 million for FY2025, which is 6.51% up from last year.
  • As of Q4 2025, Biogen's Capital Expenditures stood at $43.9 million, which was up 1170.48% from $46.2 million recorded in Q3 2025.
  • In the past 5 years, Biogen's Capital Expenditures registered a high of $92.6 million during Q1 2021, and its lowest value of $26.6 million during Q2 2025.
  • In the last 5 years, Biogen's Capital Expenditures had a median value of $48.9 million in 2021 and averaged $54.1 million.
  • In the last 5 years, Biogen's Capital Expenditures surged by 9241.19% in 2023 and then tumbled by 5283.02% in 2024.
  • Quarter analysis of 5 years shows Biogen's Capital Expenditures stood at $51.6 million in 2021, then soared by 67.44% to $86.4 million in 2022, then dropped by 24.54% to $65.2 million in 2023, then tumbled by 39.72% to $39.3 million in 2024, then rose by 11.7% to $43.9 million in 2025.
  • Its Capital Expenditures stands at $43.9 million for Q4 2025, versus $46.2 million for Q3 2025 and $26.6 million for Q2 2025.